文献速递消化系统肿瘤妇科肿瘤支持与姑息治疗

微卫星不稳定与泛癌种Lynch综合征的关联

Microsatellite Instability Is Associated With the Presence of Lynch Syndrome Pan-Cancer.
PubMed 文献 · J Clin Oncol · 2018-10-30

该研究在15,045例超过50种癌症类型的患者中,通过靶向二代测序确定微卫星状态并分析Lynch综合征相关错配修复基因的胚系突变,发现MSI-H肿瘤中Lynch综合征患病率为16.3%,且半数Lynch综合征患者的肿瘤非结直肠癌或子宫内膜癌,支持对所有MSI-H/MMR-D肿瘤患者进行胚系遗传评估。

要点

  • MSI-H肿瘤中Lynch综合征患病率为16.3%,显著高于MSI-不确定(1.9%)和MSS(0.3%)。
  • Lynch综合征合并MSI-H/I肿瘤患者中,50%的肿瘤非结直肠癌或子宫内膜癌。
  • 非结直肠癌/子宫内膜癌的Lynch综合征患者中,45%不符合基于个人/家族史的遗传检测标准。

核心结论

  • MSI-H/MMR-D可预测Lynch综合征,且涉及的肿瘤谱比目前认识的更广泛。
  • 数据支持无论癌症类型或家族史,对所有MSI-H/MMR-D肿瘤患者进行Lynch综合征的胚系遗传评估。

研究设计与样本

  • 研究纳入15,045例独特患者,涵盖超过50种癌症类型。
  • 通过靶向二代测序确定MSI状态,分为MSI-H、MSI-不确定和微卫星稳定。
  • 对匹配的胚系DNA分析Lynch综合征相关错配修复基因(MLH1、MSH2、MSH6、PMS2、EPCAM)突变。
  • 对Lynch综合征合并MSI-H/I肿瘤患者评估错配修复缺陷的免疫组化染色。

主要发现

  • MSI-H、MSI-不确定和微卫星稳定肿瘤患者中Lynch综合征的患病率分别为16.3%(53/326)、1.9%(13/699)和0.3%(37/14,020),P < .001。
  • Lynch综合征合并MSI-H/I肿瘤患者中,50%(33/66)的肿瘤非结直肠癌或子宫内膜癌,包括尿路上皮、前列腺、胰腺、肾上腺皮质、小肠、肉瘤、间皮瘤、黑色素瘤、胃和生殖细胞肿瘤。
  • 在这些非结直肠癌/子宫内膜癌患者中,45%(15/33)不符合基于个人/家族史的Lynch综合征遗传检测标准。
  • 对Lynch综合征阳性的MSI-H/I肿瘤进行免疫组化染色,98.2%(56/57)的可评估病例显示错配修复缺陷。

临床怎么用

  • 对MSI-H/MMR-D肿瘤患者,无论癌症类型或家族癌症史,均应考虑进行Lynch综合征的胚系遗传评估。
  • 该策略有助于受影响家庭的癌症监测和预防措施。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Microsatellite instability (MSI) and/or mismatch repair deficiency (MMR-D) testing has traditionally been performed in patients with colorectal (CRC) and endometrial cancer (EC) to screen for Lynch syndrome (LS)-associated cancer predisposition. The recent success of immunotherapy in high-frequency MSI (MSI-H) and/or MMR-D tumors now supports testing for MSI in all advanced solid tumors. The extent to which LS accounts for MSI-H across heterogeneous tumor types is unknown. Here, we establish the prevalence of LS across solid tumors according to MSI status. METHODS: MSI status was determined using targeted next-generation sequencing, with tumors classified as MSI-H, MSI-indeterminate, or microsatellite-stable. Matched germline DNA was analyzed for mutations in LS-associated mismatch repair genes ( MLH1, MSH2, MSH6, PMS2, EPCAM). In patients with LS with MSI-H/I tumors, immunohistochemical staining for MMR-D was assessed. RESULTS: Among 15,045 unique patients (more than 50 cancer types), LS was identified in 16.3% (53 of 326), 1.9% (13 of 699), and 0.3% (37 of 14,020) of patients with MSI-H, MSI-indeterminate, and microsatellite-stable tumors, respectively ( P < .001). Among patients with LS with MSI-H/I tumors, 50% (33 of 66) had tumors other than CRC/EC, including urothelial, prostate, pancreas, adrenocortical, small bowel, sarcoma, mesothelioma, melanoma, gastric, and germ cell tumors. In these patients with non-CRC/EC tumors, 45% (15 of 33) did not meet LS genetic testing criteria on the basis of personal/family history. Immunohistochemical staining of LS-positive MSI-H/I tumors demonstrated MMR-D in 98.2% (56 of 57) of available cases. CONCLUSION: MSI-H/MMR-D is predictive of LS across a much broader tumor spectrum than currently appreciated. Given implications for cancer surveillance and prevention measures in affected families, these data support germline genetic assessment for LS for patients with an MSI-H/MMR-D tumor, regardless of cancer type or family cancer history.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Latham A, Srinivasan P, Kemel Y, et al. Microsatellite Instability Is Associated With the Presence of Lynch Syndrome Pan-Cancer. J Clin Oncol. 2018. PMID: 30376427. doi:10.1200/JCO.18.00283

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。